Re: Disregarding the impact of nicotine on the developing brain when evaluating costs and benefits of noncombustible nicotine products

David Abrams, Allison M. Glasser, Andrea C. Villanti, Jennifer L. Pearson, Shyanika Rose, Raymond Niaura

Research output: Contribution to journalLetter

Abstract

This Letter to the Editor is in response to a letter from Ms. Flannery, titled, “Disregarding the impact of nicotine on the developing brain when evaluating costs and benefits of noncombustible nicotine products”. In our response, we address some concerns raised by Ms. Flannery, and reiterate our position in our original article. In particular, we underline the importance of a rational public health calculus that weighs beneficial and harmful consequences of policies related to noncombustible nicotine product (NNP) use. We further emphasize the need to correct misperceptions about relative risk of different products to encourage smokers to switch to NNPs. Lastly, we are explicit about our assertion that no use of any nicotine-containing products is the only way to avoid harm at any age, but that we must view this issue pragmatically for the benefit of public health.

Original languageEnglish (US)
Pages (from-to)158-159
Number of pages2
JournalPreventive Medicine
Volume120
DOIs
StatePublished - Mar 1 2019

Fingerprint

Nicotine
Cost-Benefit Analysis
Brain
Public Health
Calculi

Keywords

  • e-Cigarettes
  • Harm reduction
  • Tobacco control

ASJC Scopus subject areas

  • Epidemiology
  • Public Health, Environmental and Occupational Health

Cite this

Re : Disregarding the impact of nicotine on the developing brain when evaluating costs and benefits of noncombustible nicotine products. / Abrams, David; Glasser, Allison M.; Villanti, Andrea C.; Pearson, Jennifer L.; Rose, Shyanika; Niaura, Raymond.

In: Preventive Medicine, Vol. 120, 01.03.2019, p. 158-159.

Research output: Contribution to journalLetter

Abrams, David ; Glasser, Allison M. ; Villanti, Andrea C. ; Pearson, Jennifer L. ; Rose, Shyanika ; Niaura, Raymond. / Re : Disregarding the impact of nicotine on the developing brain when evaluating costs and benefits of noncombustible nicotine products. In: Preventive Medicine. 2019 ; Vol. 120. pp. 158-159.
@article{0fe6fda778a74b7e9f8857e405b0ae4d,
title = "Re: Disregarding the impact of nicotine on the developing brain when evaluating costs and benefits of noncombustible nicotine products",
abstract = "This Letter to the Editor is in response to a letter from Ms. Flannery, titled, “Disregarding the impact of nicotine on the developing brain when evaluating costs and benefits of noncombustible nicotine products”. In our response, we address some concerns raised by Ms. Flannery, and reiterate our position in our original article. In particular, we underline the importance of a rational public health calculus that weighs beneficial and harmful consequences of policies related to noncombustible nicotine product (NNP) use. We further emphasize the need to correct misperceptions about relative risk of different products to encourage smokers to switch to NNPs. Lastly, we are explicit about our assertion that no use of any nicotine-containing products is the only way to avoid harm at any age, but that we must view this issue pragmatically for the benefit of public health.",
keywords = "e-Cigarettes, Harm reduction, Tobacco control",
author = "David Abrams and Glasser, {Allison M.} and Villanti, {Andrea C.} and Pearson, {Jennifer L.} and Shyanika Rose and Raymond Niaura",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.ypmed.2018.12.027",
language = "English (US)",
volume = "120",
pages = "158--159",
journal = "Preventive Medicine",
issn = "0091-7435",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Re

T2 - Disregarding the impact of nicotine on the developing brain when evaluating costs and benefits of noncombustible nicotine products

AU - Abrams, David

AU - Glasser, Allison M.

AU - Villanti, Andrea C.

AU - Pearson, Jennifer L.

AU - Rose, Shyanika

AU - Niaura, Raymond

PY - 2019/3/1

Y1 - 2019/3/1

N2 - This Letter to the Editor is in response to a letter from Ms. Flannery, titled, “Disregarding the impact of nicotine on the developing brain when evaluating costs and benefits of noncombustible nicotine products”. In our response, we address some concerns raised by Ms. Flannery, and reiterate our position in our original article. In particular, we underline the importance of a rational public health calculus that weighs beneficial and harmful consequences of policies related to noncombustible nicotine product (NNP) use. We further emphasize the need to correct misperceptions about relative risk of different products to encourage smokers to switch to NNPs. Lastly, we are explicit about our assertion that no use of any nicotine-containing products is the only way to avoid harm at any age, but that we must view this issue pragmatically for the benefit of public health.

AB - This Letter to the Editor is in response to a letter from Ms. Flannery, titled, “Disregarding the impact of nicotine on the developing brain when evaluating costs and benefits of noncombustible nicotine products”. In our response, we address some concerns raised by Ms. Flannery, and reiterate our position in our original article. In particular, we underline the importance of a rational public health calculus that weighs beneficial and harmful consequences of policies related to noncombustible nicotine product (NNP) use. We further emphasize the need to correct misperceptions about relative risk of different products to encourage smokers to switch to NNPs. Lastly, we are explicit about our assertion that no use of any nicotine-containing products is the only way to avoid harm at any age, but that we must view this issue pragmatically for the benefit of public health.

KW - e-Cigarettes

KW - Harm reduction

KW - Tobacco control

UR - http://www.scopus.com/inward/record.url?scp=85061097741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061097741&partnerID=8YFLogxK

U2 - 10.1016/j.ypmed.2018.12.027

DO - 10.1016/j.ypmed.2018.12.027

M3 - Letter

VL - 120

SP - 158

EP - 159

JO - Preventive Medicine

JF - Preventive Medicine

SN - 0091-7435

ER -